Preferred hydroxymethylglutaryl-coenzyme A reductase inhibitors: treatment-modification program and outcomes

Am J Health Syst Pharm. 1999 Jul 15;56(14):1437-41. doi: 10.1093/ajhp/56.14.1437.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acyl Coenzyme A / administration & dosage*
  • Acyl Coenzyme A / economics
  • Anticholesteremic Agents / administration & dosage*
  • Anticholesteremic Agents / economics
  • Canada
  • Cost-Benefit Analysis
  • Drug Administration Schedule
  • Fatty Acids, Monounsaturated / administration & dosage*
  • Fatty Acids, Monounsaturated / economics
  • Fluvastatin
  • Humans
  • Hypercholesterolemia / drug therapy*
  • Hypercholesterolemia / economics
  • Indoles / administration & dosage*
  • Indoles / economics
  • Medical Records
  • Military Personnel*
  • Simvastatin / administration & dosage*
  • Simvastatin / economics
  • Treatment Outcome

Substances

  • Acyl Coenzyme A
  • Anticholesteremic Agents
  • Fatty Acids, Monounsaturated
  • Indoles
  • 3-hydroxy-3-methylglutaryl-coenzyme A
  • Fluvastatin
  • Simvastatin